BioSpace News Archive

Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery announced the successful first surgeries of the Spartan™ Stem and Logical™ Cup System for total hip arthroplasty.

EvoNexus, California’s leading non-profit tech incubator, selected CRISPR QC to become a portfolio company.

Chicago Pacific Founders is pleased to announce that it, along with Magruder Eye Institute and Robson Eye Institute, has formed Ascend Vision Partners.

Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the closing of its previously announced underwritten public offering for gross proceeds of approximately $13.8 million, prior to deducting underwriting discounts and commissions and offering expenses.

IN8bio, Inc. today announced the closing of its previously announced underwritten public offering of 5,394,737 shares of its common stock at a public offering price of $1.90 per share.

Viracta Therapeutics, Inc. today announced that the International Association for Research on Epstein-Barr Virus and Associated Disease (EBV Association) has elected Viracta’s Chief Scientific Officer, Ayman Elguindy , Ph.D., to its Governing Board.

OPKO Health, Inc. today announced that Jon R. Cohen, M.D., is retiring from his role as Executive Chairman and Chief Executive Officer of BioReference Laboratories and Senior Vice President and a Director of OPKO.

PAVmed Inc. today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) and Veris Health Inc. (“Veris”), and presented financial results for the three and six months ended June 30, 2022.

Lotus Bio-Technology Development Corp. (OTC:LBTD) is excited to announce today that the company has begun the process of changing its name from Lotus Bio-Technology Development Corp. to Boomerang Corporation.

Iterum Therapeutics plc announced that it will effect a 1-for-15 reverse share split of its outstanding ordinary shares at 5.00 p.m. Eastern Time on August 17, 2022, which will be effective for trading purposes on the Nasdaq Capital Market as of the commencement of trading on August 18, 2022.